4D Molecular Therapeutics FDMT EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's EPS (basic)?
- 4D Molecular Therapeutics (FDMT) reported EPS (basic) of -$1.01 in Q1 2026.
- How has 4D Molecular Therapeutics's EPS (basic) changed year-over-year?
- 4D Molecular Therapeutics's EPS (basic) decreased by 17.4% year-over-year, from -$0.86 to -$1.01.
- What is the long-term trend for 4D Molecular Therapeutics's EPS (basic)?
- Over 3 years (2021 to 2024), 4D Molecular Therapeutics's EPS (basic) has grown at a 5.1% compound annual growth rate (CAGR), from -$2.57 to -$2.98.
- What does EPS (basic) mean?
- Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.